27 Mar

Analysts Drastically Reduced Target Price for Opko Health in March

WRITTEN BY Margaret Patrick

Analysts’ recommendations and target price

Wall Street analysts expect an upside potential of 107.39% for Opko Health (OPK) based on the company’s closing price on March 26. In 2019, analysts revised downwards the company’s target price from $10.00 in January and February to $5.33 in March. The current consensus analyst recommendation for the stock is a “strong buy.”

Analysts Drastically Reduced Target Price for Opko Health in March

Of the three analysts covering Opko Health, two are recommending a “strong buy,” and one analyst is recommending a “buy.” On March 26, Opko Health closed at $2.57, 1.98% higher than its previous closing price, 10.06% higher than its 52-week low of $2.34 and 59.84% lower than its 52-week high of $6.40. The company’s market capitalization is $1.70 billion.

Based on its closing price on March 26, Opko Health has reported returns of 2.39% in the last week, -9.51% in the last month, and 0.39% in the last quarter. The company has reported returns of -40.51% in the last half year, -27.20% in the last year, and -14.62% YTD.

Recent stock price movements

In its fourth quarter, Opko Health reported revenues of $221.90 million, a YoY rise of 14.56% but lower than the consensus estimate by $23.37 million. The company reported non-GAAP EPS of -$0.13, which was lower than the consensus estimate by $0.04. After its fourth-quarter earnings announcement on February 27, the company’s share price declined to $2.78  from $2.83 on the previous day. The stock further slipped to $2.55 on February 28.

On March 21, Opko Health issued a press release announcing positive top-line results from the phase 2 trial evaluating investigational injectable therapy OPK88003 in the obesity and type 2 diabetes indication. Thereafter, the company’s stock price closed at $2.72 on March 21, 10.57% higher than its previous closing price.

Latest articles

Goldman Sachs (GS) settled a lawsuit that alleged it rigged bond prices. Also, Deutsche Bank agreed to pay a fine of $15 million to settle a lawsuit.

In the November 15 premarket trading session, Amarin Corporation (AMRN) stock rose more than 7%, caused by the FDA positive decision for Vascepa.

In the November 14 trading session, Aurora Cannabis (ACB) stock fell 12.7% from the previous session during after-hours trading.

Strategy Analytics reported that Apple could lead the 5G smartphone market in 2020, outshining Samsung—the current leader in the global 5G market.

This week has been tough for the cannabis sector. Cronos Group and Canopy Growth reported lower-than-expected earnings, and the sector ETFs dropped.

Yesterday, Argus Research upgraded Uber stock from “hold” to “buy.” Let's look at Uber and Lyft’s recent analyst rating changes.